Bristol-Myers
Squibb Company BMY today reported results from the Phase 3
randomized, double-blind clinical trial (Study 043) comparing Yervoy 10
mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in
patients with advanced metastatic castration-resistant prostate cancer
(mCRPC) who have received prior treatment with docetaxel. The study's
primary endpoint of overall survival (OS) did not reach statistical
significance (HR = 0.85; 95% CI = 0.72-1.00; p = 0.053). However,
anti-tumor activity was observed across some efficacy endpoints,
including progression free-survival. These data will be presented at the
2013 European Cancer Congress in an oral session on September 28
(Abstract # 2850).
Treatment-related adverse events were common, with most being
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in